Thus, systematic screening of the constitutive levels of phospho-Ku70 in CLL patients who have never been treated could potentially be a very useful marker for clinicians to determine if front-line therapy should be replaced by other treatments (such as immunotherapy). The gene discussed is XRCC6; the disease is B-cell chronic lymphocytic leukemia.